SuperworthAllogene Therapeutics market cap ALLO
Share price times shares outstanding: what the whole company sells for, since 2018.
- Today, Oct 23, 2026
- $431.9M
- Highest close in our data
- $6.8B
- May 2020
Allogene Therapeutics is worth $431.9M at the close on Oct 23, 2026, at $1.25 a share.
That is up 62% over the last year and down 82% over five years.
Its highest close in our data was $6.8B in May 2020.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $431.9M | $303.4M | $749M | +39% |
| 2025 | $310.1M | $227.5M | $457.1M | −32% |
| 2024 | $459.2M | $362.2M | $885.1M | −15% |
| 2023 | $540.2M | $415.6M | $1.1B | −40% |
| 2022 | $907.1M | $859.5M | $2.5B | −57% |
| 2021 | $2.1B | $1.9B | $5.4B | −40% |
| 2020 | $3.5B | $2.4B | $6.8B | +10% |
| 2019 | $3.2B | $3B | $4B | +2% |
| 2018 | $3.1B | $2.9B | $3.8B | n/a |
Against its peers
Companies in Biotechnology nearest Allogene Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| ALLOAllogene Therapeutics | $431.9M |
| MGTXMeiraGTx | $884.6M |
| PLXProtalix BioTherapeutics | $205.5M |
| VCELVericel | $2.2B |
| ADMAAdma Biologics | $2.4B |
| Peer median | $1.5B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Allogene Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.